Exchange Traded Concepts LLC Invests $287,000 in OraSure Technologies, Inc. (NASDAQ:OSUR)

Exchange Traded Concepts LLC purchased a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 79,469 shares of the medical instruments supplier's stock, valued at approximately $287,000. Exchange Traded Concepts LLC owned approximately 0.11% of OraSure Technologies as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Atom Investors LP purchased a new stake in shares of OraSure Technologies in the 3rd quarter valued at $49,000. Creative Planning bought a new position in shares of OraSure Technologies during the third quarter valued at about $54,000. Mackenzie Financial Corp bought a new position in shares of OraSure Technologies during the second quarter valued at about $72,000. Intech Investment Management LLC bought a new stake in shares of OraSure Technologies in the 3rd quarter valued at about $84,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in OraSure Technologies by 78.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier's stock valued at $123,000 after acquiring an additional 12,604 shares during the period. Institutional investors own 93.50% of the company's stock.

OraSure Technologies Price Performance

OraSure Technologies stock traded up $0.10 during trading hours on Tuesday, reaching $4.01. The stock had a trading volume of 387,534 shares, compared to its average volume of 911,042. The company has a fifty day simple moving average of $3.81 and a 200-day simple moving average of $4.07. OraSure Technologies, Inc. has a 52 week low of $3.52 and a 52 week high of $8.04. The stock has a market cap of $299.11 million, a PE ratio of 26.73 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The company had revenue of $39.92 million during the quarter, compared to analyst estimates of $38.97 million. During the same period in the prior year, the business posted $0.27 earnings per share. OraSure Technologies's revenue for the quarter was down 55.2% on a year-over-year basis. Research analysts predict that OraSure Technologies, Inc. will post -0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut OraSure Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, January 28th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.